Maria Eleni Manthou

Prof. Maria Eleni Manthou

Aristotle Univeristy of Thessaloniki
orcid
Aristotle University of Thessaloniki, Laboratory of Histolog...

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Iasonas DermitzakisIasonas Dermitzakis
Iasonas Dermitzakis
Paschalis TheotokisPaschalis Theotokis
Paschalis Theotokis
Paschalis EvangelidisPaschalis Evangelidis
Paschalis Evangelidis
EDEfthymia Delilampou
Efthymia Delilampou
Nikolaos EvangelidisNikolaos Evangelidis
Nikolaos Evangelidis
Maria Eleni ManthouMaria Eleni Manthou
Maria Eleni Manthou
Being immune privileged, the central nervous system (CNS) is constituted by unique parenchymal and non-parenchymal tissue-resident macrophages, namely, microglia and border-associated macrophages (BAMs), respectively. BAMs are found in the choroid plexus, meningeal and perivascular spaces, playing critical roles in maintaining CNS homeostasis while being phenotypically and functionally distinct from microglial cells. Although the ontogeny of microglia has been largely determined, BAMs need comparable scrutiny as they have been recently discovered and have not been thoroughly explored. Newly developed techniques have transformed our understanding of BAMs, revealing their cellular heterogeneity and diversity. Recent data showed that BAMs also originate from yolk sac progenitors instead of bone marrow-derived monocytes, highlighting the absolute need to further investigate their repopulation pattern in adult CNS. Shedding light on the molecular cues and drivers orchestrating BAM generation is essential for delineating their cellular identity. BAMs are receiving more attention since they are gradually incorporated into neurodegenerative and neuroinflammatory disease evaluations. The present review provides insights towards the current understanding regarding the ontogeny of BAMs and their involvement in CNS diseases, paving their way into targeted therapeutic strategies and precision medicine.

Verified
Journal Article
Open access
PDF file
Iasonas DermitzakisIasonas Dermitzakis
Iasonas Dermitzakis
Maria Eleni ManthouMaria Eleni Manthou
Maria Eleni Manthou
SMSoultana Meditskou
Soultana Meditskou
MTMarie-Ève Tremblay
Marie-Ève Tremblay
SPSteven Petratos
Steven Petratos
Paschalis TheotokisPaschalis Theotokis
Paschalis Theotokis
Microglia belong to tissue-resident macrophages of the central nervous system (CNS), representing the primary innate immune cells. This cell type constitutes ~7% of non-neuronal cells in the mammalian brain and has a variety of biological roles integral to homeostasis and pathophysiology from the late embryonic to adult brain. Its unique identity that distinguishes its “glial” features from tissue-resident macrophages resides in the fact that once entering the CNS, it is perennially exposed to a unique environment following the formation of the blood–brain barrier. Additionally, tissue-resident macrophage progenies derive from various peripheral sites that exhibit hematopoietic potential, and this has resulted in interpretation issues surrounding their origin. Intensive research endeavors have intended to track microglial progenitors during development and disease. The current review provides a corpus of recent evidence in an attempt to disentangle the birthplace of microglia from the progenitor state and underlies the molecular elements that drive microgliogenesis. Furthermore, it caters towards tracking the lineage spatiotemporally during embryonic development and outlining microglial repopulation in the mature CNS. This collection of data can potentially shed light on the therapeutic potential of microglia for CNS perturbations across various levels of severity.
1

13 January 2019 in Journal of Tissue Engineering and Regenerative Medicine
Verified
Journal Article
Closed access
PDF file
KTKonstantinos Theodoridis
Konstantinos Theodoridis
EAEleni Aggelidou
Eleni Aggelidou
TVTheofanis Vavilis
Theofanis Vavilis
Maria Eleni ManthouMaria Eleni Manthou
Maria Eleni Manthou
ATAntonios Tsimponis
Antonios Tsimponis
AKAristeidis Kritis
Aristeidis Kritis

1 November 2019 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
KTKonstantinos Theodoridis
Konstantinos Theodoridis
EAEleni Aggelidou
Eleni Aggelidou
Maria Eleni ManthouMaria Eleni Manthou
Maria Eleni Manthou
EDEfterpi Demiri
Efterpi Demiri
ABAthina Bakopoulou
Athina Bakopoulou
AKAristeidis Kritis
Aristeidis Kritis

15 March 2013 in Journal of Neurotrauma
Verified
Journal Article
Closed access
FWFelicitas Wirth
Felicitas Wirth
GSGreta Schempf
Greta Schempf
GSGregor Stein
Gregor Stein
KWKatharina Wellmann
Katharina Wellmann
Maria Eleni ManthouMaria Eleni Manthou
Maria Eleni Manthou
ESEckhard Schönau
Eckhard Schönau
Whole-body vibration (WBV) is a relatively novel form of exercise used to improve neuromuscular performance in healthy individuals. Its usefulness as a therapy for patients with neurological disorders, in particular spinal cord injury (SCI), has received little attention in clinical settings and, surprisingly, even less in animal SCI models. We performed severe compression SCI at a low-thoracic level in Wistar rats followed by daily WBV starting 7 (10 rats) or 14 (10 rats) days after injury (WBV7 and WBV14, respectively) and continued over a 12-week post-injury period. Rats with SCI but no WBV training (sham, 10 rats) and intact animals (10 rats) served as controls. Compared to sham-treated rats, WBV did not improve BBB score, plantar stepping, or ladder stepping during the 12-week period. Accordingly, WBV did not significantly alter plantar H-reflex, lesion volume, serotonergic input to the lumbar spinal cord, nor cholinergic or glutamatergic inputs to lumbar motoneurons at 12 weeks after SCI. However, compared to sham, WBV14, but not WBV7, significantly improved body weight support (rump-height index) during overground locomotion and overall recovery between 6–12 weeks and also restored the density of synaptic terminals in the lumbar spinal cord at 12 weeks. Most remarkably, WBV14 led to a significant improvement of bladder function at 6–12 weeks after injury. These findings provide the first evidence for functional benefits of WBV in an animal SCI model and warrant further preclinical investigations to determine mechanisms underpinning this noninvasive, inexpensive, and easily delivered potential rehabilitation therapy for SCI.

Verified
Journal Article
Open access
PDF file
Iasonas DermitzakisIasonas Dermitzakis
Iasonas Dermitzakis
Maria Eleni ManthouMaria Eleni Manthou
Maria Eleni Manthou
SMSoultana Meditskou
Soultana Meditskou
DMDIMOSTHENIS MILIARAS
DIMOSTHENIS MILIARAS
EKEvangelia Kesidou
Evangelia Kesidou
Paschalis TheotokisPaschalis Theotokis
Paschalis Theotokis
The mammalian central nervous system (CNS) coordinates its communication through saltatory conduction, facilitated by myelin-forming oligodendrocytes (OLs). Despite the fact that neurogenesis from stem cell niches has caught the majority of attention in recent years, oligodendrogenesis and, more specifically, the molecular underpinnings behind OL-dependent myelinogenesis, remain largely unknown. In this comprehensive review, we determine the developmental cues and molecular drivers which regulate normal myelination both at the prenatal and postnatal periods. We have indexed the individual stages of myelinogenesis sequentially; from the initiation of oligodendrocyte precursor cells, including migration and proliferation, to first contact with the axon that enlists positive and negative regulators for myelination, until the ultimate maintenance of the axon ensheathment and myelin growth. Here, we highlight multiple developmental pathways that are key to successful myelin formation and define the molecular pathways that can potentially be targets for pharmacological interventions in a variety of neurological disorders that exhibit demyelination.